We are pleased to share that TIEFENBACHER GROUP is committed to becoming climate neutral by the end of 2025*. As a value-driven healthcare company, dedicated to improving the life of patients worldwide, we recognize the importance of taking action to address the urgent climate crisis we face today. To achieve this goal, we are implementing a comprehensive sustainability strategy that includes the following measures, among others:

As our biggest driver of the carbon footprint is energy consumption, large-scale solar panels will be installed on our manufacturing facilities in Cyprus and India. Any electricity that cannot be produced in-house and must be purchased will be purely green electricity. In addition, we are implementing energy saving and efficiency measures – especially at our production sites. Furthermore, all company vehicles will be exclusively electric in the future. With these measures, we will already achieve a great interim goal: reducing our emissions by 80% by January 2024.

We believe that this is not only the right thing to do for the planet but also the right thing to do for our business. Being commercially successful and operating responsibly by becoming climate neutral is how we generate sustainable returns. We look forward to sharing more updates on our progress towards this important goal in the coming months and years.

*Scope 1 and 2 according to GHG as well as business travel and employee commuting

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve patients’ lives by making pharmaceuticals more affordable, more available and better than ever before.  

For further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets please contact Tiefenbacher Group: info@aet.eu